Novo Nordisk (CPH:NOVO-B) gains as South Africa copycat order tops Ozempic, Wegovy local sales
Novo Nordisk’s B shares surged 9.9% in three sessions after a South African court halted rival iDexis from supplying about 84,500 compounded semaglutide units monthly—more than Novo’s Ozempic and Wegovy sales combined in the country—potentially shifting demand to Novo, though price sensitivity and an interim order pose risks.